On or around 09/20/2019 (Ongoing date of last review)
Filing Date: December 21, 2018
Plaintiff's law firm issued a press release on December 21, 2018, announcing the filing of the lawsuit. According to the press release, the Complaint alleges that, during the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts. Specifically, the Complaint alleges that throughout the Class Period Allergan concealed from investors the fact that the Company's CE Mark for its textured breast implants and tissue expanders was expiring in Europe.
On March 21, 2019, the Court issued an Order consolidating cases and appointing Lead Plaintiff and Counsel. Lead Plaintiff filed a consolidated amended Complaint on April 19. Defendants filed a Motion to Dismiss the consolidated amended Complaint on May 24. On September 20, the Court issued an Order granting in part and denying in part the Motion to Dismiss.
Company & Securities Information
Defendant: Allergan plc
Industry: Biotechnology & Drugs
Ticker Symbol: AGN
Company Market: New York SE
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.